Experimental drug duo targets Hard-to-Treat cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Ability to provide and document informed consent and willing and able to comply with all study procedures. * Participants diagnosed with advanced solid tumors including but not limited to metastatic castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer and renal cell carcinoma. * Participants have received approved therapies according to their diagnosis. * Participants must have an available tumor tissue sample. A fresh tumor biopsy may be performed if no archival sample is available. * Eastern Cooperative Oncology Group performance status of less than or equal to 2. * Life expectancy of at least 12 weeks. * Evidence of measurable tumor for evaluation * Acceptable end organ function according to laboratory results. * Patients must agree to use highly-effective contraception during the study, and not donate sperm or ova. Exclusion Criteria: * Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures. * Another malignancy that required treatment within the past 2 years. Participants who have had curative therapy for non-melanomatous skin cancer, localized prostate cancer (Gleason score \< 6), or carcinoma in situ are eligible for the study. * Active viral, bacterial, or fungal infection requiring systemic treatment within 1 week of initiation of study drug. Participants are eligible after SARS CoV 2-related symptoms have fully recovered for ≥ 72 hours. * History of immunodeficiency. Participants with HIV are eligible if they have a CD4+ count ≥ 300/µL, undetectable viral load, and maintained on antiretroviral therapy for a minimum of 4 weeks. * Prior autologous/allogeneic stem cell or tissue/solid organ transplant * Prior treatment with MGD009, enoblituzumab, or other B7-H3 targeted agents for cancer. * Clinically significant cardiovascular disease, lung compromise, venous insufficiency, or gastrointestinal disorders. * Participants with greater than Grade 1 peripheral neuropathy. * Participants who have a history of severe adverse events (AEs) from immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or CTLA-4 inhibitors). All other AEs from prior immune checkpoint inhibitors must be resolved to Grade 1 or less. Participants with any grade neurologic toxicity from prior immune checkpoint inhibitors are excluded. * Pleural effusion or ascites. Trace pleural or peritoneal fluid is not exclusionary. * History of Guillain-Barre syndrome, myasthenia gravis, or other autoimmune sensory or motor neuropathies.